Hospital Quironsalud Barcelona — Clinical Trial Site

147 Registered trials

55 Currently recruiting

Organisation

Hospital Quironsalud Barcelona

Location

Barcelona, Spain

Identifier

ORG-100042252

Address

Placa D'alfonso Comin 5-7, 08023, Spain

Departments

-
#3309: Oncology
#3457: Medicina Interna
2805: Medicina Interna
3131: medicina interna
34005: Next Oncology. Phase I Unit
Breast and skin cancer Unit
Departamento de Ginecología
Endocrinología
Endocrinology
Institute of Oncology Barcelona
Instituto de Oncología de Barcelona
Internal Medicine
IOB Institute of Oncology
Medical Oncologist
Medical Oncology
Medical Oncology Department
Medical Oncology, Phase I unit Next Oncology
Medicina Interna
N/A
Next Oncology
Next Oncology Barcelona
Next Oncology Barcelona IOB
NEXT Oncology Phase I unit - IOB Hospital Quironsalud Barcelona
Next Oncology. IOB
Next Oncology. Phase I Unit. IOB - Hospital Quironsalud Barcelona
Oncología
Oncología Médica
Oncología Médica. Unidad NEXT Oncology
Oncology
Oncology - Phase I Unit
Oncology Department
Oncology Medical Service
Oncology Service
Pediatria
Phase I Unit
Phase I Unit - NEXT Oncology Barcelona
Phase Unit I
Rheumatology
Servicio de Medicina Interna
Servicio de Oncologia
Servicio de Oncología - NEXT Oncology
Unidad de cancer genitourinario
Unidad de Ensayos Fase I
Unidad Ensayos Fase I - Oncology

Clinical trials at this site (147)

Search interface

Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in com… Ended

2024-512575-12-00 ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS 9 2020-11-25
A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with F… Ended

2024-515379-36-00 Metastatic pancreatic ductal adenocarcinoma 9 2020-08-04
Study of U3-1402 in subjects with non-small cell lung cancer Ended

2024-511205-33-00 METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER 3 2020-05-18
Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2… Ended

2023-505042-25-00 Locally advanced (inoperable) or metastatic HR+/HER2 br 5 2020-05-05
GEN1046 Safety Trial in Patients With Malignant Solid Tumors Ended

2023-509059-15-00 Malignant solid tumors: endometrial carcinoma (EC), uro 7 2019-04-30
Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Ended

2024-511204-16-00 Metastatic breast cancer 5 2019-01-23
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended

2024-516889-11-00 non-small cell lung cancer (NSCLC) 4 2025-05-21
AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation Ended

2024-515391-12-00 Advanced Solid Tumors with AKT1 E17K Mutation 1 2025-03-15
A Study of ZL-1218 with or without Pembrolizumab in Subjects with Advanced Solid Tumor Cancers to Find a Suitable Dose and to Test How Diffe… Ended

2022-503102-20-00 Advanced solid tumors 1 2025-03-10
M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) Ended

2024-514155-15-00 Advanced solid tumors and colorectal cancer 3 2025-01-08
A Study of HST-1011 For The Treatment Of People With Advanced Cancers That Are Not Benefiting From Other Standard of Care Therapies Ended

2023-503731-18-00 Advanced Solid Tumors 7 2024-09-30
A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni… Ended

2023-505755-40-00 Chronic kidney disease 4 2024-08-16
Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers Ended

2023-505762-29-00 Virus diseases 5 2024-08-09
A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced l… Ended

2023-509644-10-00 Advanced Non-small Cell Lung Cancer 9 2024-06-27
A study on the immune response and safety of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccin… Ended

2023-510196-59-00 Respiratory Syncytial Virus Infections 5 2024-06-15
First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer Ended

2023-504012-16-00 Unresectable Locally Advanced or Metastatic Cancer 7 2024-04-29
RVU 120 (SEL120) to be tested in for treatment patients with solid tumors who have failed previous available standard therapy Ended

2024-515131-30-00 Relapsed / Refractory Metastatic or Advanced Solid Tumo 4 2023-12-18
A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer Ended

2022-502125-17-00 Advanced solid tumors 1 2023-10-16
Study of GS-4528 for Adults With Solid Tumors Ended

2022-502070-16-00 Solid Tumors 1 2023-10-02
A double-blind, randomised, dose-finding trial to assess the efficacy, safety and pharmacokinetics of a single dose of albaconazole versus f… Ended

2023-504727-32-00 Acute vulvovaginal candidiasis 4 2023-09-18
A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat… Ended

2022-501988-40-00 RSV-associated (subtypes A and B) disease in adults age 5 2023-08-17